Abstract
Summary: Objective: Thyroid hormones and progesterone both influence core temperature, metabolism and are crucial during pregnancy. Our objective was to discover whether progesterone therapy caused changes in thyroid physiology compared with placebo.Design: Post hoc analysis from a randomized (1:1) placebo‐controlled 12‐week trial of oral micronized progesterone (Progesterone, 300 mg/d at bedtime) for hot flushes (vasomotor symptoms, VMS) conducted in an academic medical centre.Patients: Postmenopausal euthyroid, healthy (without cardiovascular diseases or risks) women, 1–11 years since last flow on no thyroid or ovarian hormone therapy with VMS participated.Measurements: Primary outcomes were final and 12‐week changes in TSH, FreeT3 and FreeT4 on progesterone vs placebo.Results: Women with thyroid data (69 of 133 in original trial) were randomized to progesterone (n = 39) or placebo (n = 30)—baseline thyroid values were normal. There were no VMS‐thyroid interactions—VMS Score (number × intensity) did not correlate with TSH, FreeT3 or FreeT4 (Spearman's rank correlations: −0.03 to −0.19, respectively; all P > 0.15). At 12 weeks on progesterone, TSH levels tended to be lower (1.7 mU) than on placebo (2.2), P = 0.06; FreeT4 levels were higher (16.4 pmol/l) than on placebo (15.3), P = 0.02. FreeT3 was unchanged throughout. Analysis of covariance showed a significant increase in FreeT4 on progesterone (+2.5 pmol/l; 1.9–3.0) vs on placebo (+1.7; 1.1–2.4) with 95% CI of difference = 0.8 pmol/l [0.0, 1.6], P = 0.04.Conclusions: Progesterone caused a significant FreeT4 increase that was discovered during this randomized controlled VMS trial. The clinical importance of this increased FreeT4 level remains to be documented. Registered at ClinialTrials.gov#NCT00152438.

This publication has 27 references indexed in Scilit: